Navigation Links
Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
Date:8/27/2008

SCOTTSDALE, Ariz., Aug. 27 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled "Thought Leader Insight & Analysis: Breast Cancer," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area. MedPredict interviewed renowned North American and European breast cancer thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs. They address the following questions:

-- Has Novartis jumped ahead of Amgen in developing a breast cancer drug that provides a mortality benefit and preserves bone? MedPredict's panel debates the implications of Novartis' positive zoledronic acid (Zometa) data presented at ASCO 2008.

-- How prevalent is osteonecrosis of the jaw with antiresorptives, and how will this affect their usage in breast cancer?

-- How is triple negative breast cancer being treated, and where are the opportunities for development in this subtype?

-- What are the best approaches for development of inhibitors of mTOR, IGF1R, EGFR, PARP-1, HSP90, Src, angiogenesis, FA2, hedgehog, and vaccines?

"This report will provide essential strategic insight for those involved in development of breast cancer therapies," according to MedPredict President Dr. Jeffrey Berk. "Our report discusses ongoing clinical programs, and offers insight into which of the many new drugs in development are likely to be significant improvements over current options."

Companies included in this report: Abbott (ABT-888, ABT-999, A-928605), Abraxis/AstraZeneca (Abraxane), Amgen (denosumab, AMG-479), AstraZeneca (Arimidex, olaparib, saracatinib), Bayer-Schering (Bonefos), BiPar (BSI-201, BSI-401), Boehringer Ingelheim (Tovok), Bristol-Myers Squibb (brivanib, BMS-754807, Sprycel, Ixempra), BMS/Imclone (Erbitux), Exelixis (XL-765, XL-647), Genentech (Avastin, GDC-0941, Herceptin, pertuzumab, trastuzumab-DM1), GlaxoSmithKline (Tykerb), Imclone (IMC-A12, IMC-1121B), Kosan (tanespimycin), Merck (Fosamax, odanacatib, MK-0646), Myriad (BRCA1/BRCA2 Screening), Merck/Ariad (deforolimus), Novartis (Zometa, Femara, everolimus, patupilone, TAE-266), OSI (OSI-906), Pfizer (Aromasin, Sutent, Tarceva, CP-751871), Pierre Fabre (Javlor), Roche/GSK (Boniva), Roche (Xeloda), Sanofi-Aventis (AVE-1642), Schering-Plough (SCH-717454), and Wyeth (Torisel, neratinib).

The full report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The Michigan Life Sciences Pipeline Adds More Resources On Its Website
2. Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
3. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
4. BioMS Medical Provides Update On Pipeline Products
5. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
7. Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline
8. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
9. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
10. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
11. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):